These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12678836)

  • 21. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors.
    Moran TH; Bi S
    Philos Trans R Soc Lond B Biol Sci; 2006 Jul; 361(1471):1211-8. PubMed ID: 16815799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice.
    Clerc P; Coll Constans MG; Lulka H; Broussaud S; Guigné C; Leung-Theung-Long S; Perrin C; Knauf C; Carpéné C; Pénicaud L; Seva C; Burcelin R; Valet P; Fourmy D; Dufresne M
    Endocrinology; 2007 Mar; 148(3):1039-49. PubMed ID: 17122076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholecystokinin regulates satiation independently of the abdominal vagal nerve in a pig model of total subdiaphragmatic vagotomy.
    Ripken D; van der Wielen N; van der Meulen J; Schuurman T; Witkamp RF; Hendriks HF; Koopmans SJ
    Physiol Behav; 2015 Feb; 139():167-76. PubMed ID: 25449395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unraveling the obesity of OLETF rats.
    Moran TH
    Physiol Behav; 2008 Apr; 94(1):71-8. PubMed ID: 18190934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholecystokinin-8 inhibits methamphetamine-induced neurotoxicity via an anti-oxidative stress pathway.
    Wen D; An M; Gou H; Liu X; Liu L; Ma C; Cong B
    Neurotoxicology; 2016 Dec; 57():31-38. PubMed ID: 27565679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for design of non peptide CCK1R agonist/antagonist ligands.
    García-López MT; González-Muñiz R; Martín-Martínez M; Herranz R
    Curr Top Med Chem; 2007; 7(12):1180-94. PubMed ID: 17584140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents.
    Pierson ME; Comstock JM; Simmons RD; Kaiser F; Julien R; Zongrone J; Rosamond JD
    J Med Chem; 1997 Dec; 40(26):4302-7. PubMed ID: 9435899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracerebroventricular cholecystokinin A-receptor antagonist does not reduce satiation by endogenous CCK.
    Brenner LA; Ritter RC
    Physiol Behav; 1998 Feb; 63(4):711-6. PubMed ID: 9523920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholecystokinin receptors regulate sperm protein tyrosine phosphorylation via uptake of HCO3-.
    Zhou Y; Ru Y; Shi H; Wang Y; Wu B; Upur H; Zhang Y
    Reproduction; 2015 Oct; 150(4):257-68. PubMed ID: 26175429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral apelin-13 administration inhibits gastrointestinal motor functions in rats: The role of cholecystokinin through CCK
    Bülbül M; Sinen O; Birsen İ; Izgüt-Uysal V
    Neuropeptides; 2017 Jun; 63():91-97. PubMed ID: 28012561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prolonged cholecystokinin administration on rat pituitary-adrenocortical axis: role of the CCK receptor subtypes 1 and 2.
    Malendowicz LK; Spinazzi R; Majchrzak M; Nowak M; Nussdorfer GG; Ziolkowska A; Macchi C; Trejter M
    Int J Mol Med; 2003 Dec; 12(6):903-9. PubMed ID: 14612964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
    Altar CA; Boyar WC
    Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a CCK1R-membrane nanoparticle as a fish-out tool for bioactive peptides.
    Staljanssens D; Rico CA; Park M; Van Camp J; Yu N; Huber T; Sakmar TP; Smagghe G
    Peptides; 2015 Jun; 68():219-27. PubMed ID: 25451329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
    Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.
    Desai AJ; Harikumar KG; Miller LJ
    J Biol Chem; 2014 Jun; 289(26):18314-26. PubMed ID: 24825903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of cholecystokinin in feeding and lactation.
    Lindén A
    Acta Physiol Scand Suppl; 1989; 585():i-vii, 1-49. PubMed ID: 2603747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview. Cholecystokinin and eating.
    Beglinger C
    Curr Opin Investig Drugs; 2002 Apr; 3(4):587-8. PubMed ID: 12090729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCK1 antagonists: are they ready for clinical use?
    Peter SA; D'Amato M; Beglinger C
    Dig Dis; 2006; 24(1-2):70-82. PubMed ID: 16699265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of a peripherally acting cholecystokinin1 receptor antagonist on food intake in rats: implications for the cholecystokinin-satiety hypothesis.
    Ebenezer IS
    Eur J Pharmacol; 2003 Feb; 461(2-3):113-8. PubMed ID: 12586206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.